New Technology

Business Unit New Technology

The "New Technology" business unit comprises the core technologies of AVA LifeScience to identify and develop our products.
The business unit homes our proprietary technology platform for the selection of NextGenMonoclonal® antibodies with unique target specifity and the ability to discriminate single amino acid changes in target proteins.
We also develop the tools and strategies for effective companion diagnostics.
Our current focus is on B cell malignancies.  


NextGenMonoclonals ®

AVA-mAb01 is the first product developed by using our NextGenMonoclonals platform technology.

AVA-mAb01 is directed against a specific target structure on the surface of chronic lymphocytic leukemia (CLL) B cells. The high specificity of this product offers the possibility to stratify patients and opens the way for a targeted therapy.


Our current focus is on B cell malignancies where we generate tumor-specific antibodies targeting aggressive subgroups of chronic lymphatic leukemia (CLL).

In addition, we are in the planning phase to address other B cell malignancies such as mantle cell lymphoma and follicular lymphoma.

Our future perspective is on the development of specific antibodies for autoimmune diseases such as multiple sclerosis or rheumatoid arthritis.